Literature DB >> 24184153

Characterization of a pro-angiogenic, novel peptide from Russell's viper (Daboia russelii russelii) venom.

Ashis K Mukherjee1, Suvro Chatterjee2, Syamantak Majumder2, Debashree Saikia3, Rupamoni Thakur3, Anupam Chatterjee4.   

Abstract

Present report shows for the first time on the induction of in vitro angiogenesis by a 3.9 kDa novel peptide (RVVAP) purified from Russell's viper venom. Secondary structure of RVVAP is made up of 36.8% α-helix, 33.3% β pleated sheets and 29.9% turns. Optimum angiogenesis and significant elevation in endothelial migration were observed at 50 ng/ml of RVVAP treatment; above this concentration, progressive decrease in wound healing was noted. RVVAP (1.0 μg/ml) was non-cytotoxic to U87-MG, HeLa and HT-29 cells; however, increasing the RVVAP concentration above 500 ng/ml resulted in induction of chromosomal aberrations and delay in cell cycle kinetics of Chinese hamster ovary cells.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Chromosomal aberration; Cytotoxicity; Russell's viper; Wound healing

Mesh:

Substances:

Year:  2013        PMID: 24184153     DOI: 10.1016/j.toxicon.2013.10.024

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  2 in total

1.  Anticoagulant mechanism, pharmacological activity, and assessment of preclinical safety of a novel fibrin(ogen)olytic serine protease from leaves of Leucas indica.

Authors:  Debananda Gogoi; Neha Arora; Bhargab Kalita; Rahul Sarma; Taufikul Islam; Sidhhartha S Ghosh; Rajlakshmi Devi; Ashis K Mukherjee
Journal:  Sci Rep       Date:  2018-04-18       Impact factor: 4.379

2.  Acidic Phospholipase A2-Peptide Derivative Modulates Oxidative Status and Microstructural Reorganization of Scar Tissue after Cutaneous Injury.

Authors:  Estefanny Ruiz García; Edvaldo Barros; Stephanie Stransky; Carlos Chávez-Olórtegui; Mariella Bontempo Freitas; Rômulo Dias Novaes; Reggiani Vilela Gonçalves
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-11       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.